Skip to main content
OpenTrials
Completed

NCT Number: NCT03129594

Plasma Glucagon-like Peptide-1 Levels and Acute Myocardial Infarction

GLP-1(9-36) amide and (9-37), which was previously thought to be the inactive metabolite of GLP-1, also exerts cardioprotective effects. Direct administration of GLP-1(9-36) during reperfusion reduced ischaemic damage in isolated hearts and increased cGMP release, vasodilatation and coronary flow in AMI mouse model, one may speculate that total GLP-1 level may associate with adverse cardiovascular events in AMI patients, the hypothesis is therefore tested in this study.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Coronary Angiography Glucagon-like Peptide-1

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • consecutive patients of acute AMI come to our department,absent of cardiogenic shock, and survival for at least 24 h after PCI treatment.

Exclusion criteria

  • patients with cancer, and patients who were taking a DPP4 inhibitor or a glucagon-like peptide-1 (GLP-1) analogue

Treatment and study plan

plasma glucagon-like peptide-1 levels

Diagnostic Test

The plasma GLP-1 levels was determined by enzymatic assays.

Primary outcomes

  1. all-cause mortality

    Time frame: The median follow-up was 29 months

  2. cardiovascular mortality

    Time frame: The median follow-up was 29 months

Secondary outcomes

  1. non-cardiovascular mortality

    Time frame: The median follow-up was 29 months

  2. Myocardial infarction

    Time frame: The median follow-up was 29 months

  3. heart failure readmission

    Time frame: The median follow-up was 29 months

    readmission to any hospital due to diagnosed heart failure

  4. Stroke

    Time frame: The median follow-up was 29 months

    defined using the World Health Organization criteria

  5. repeated revascularization

    Time frame: The median follow-up was 29 months

    defined as repeated PCI or bypass grafting of not only infarct related artery

Sponsors and collaborators

Lead sponsor

Chinese PLA General Hospital

Other

Registry information

Official study title

Prognostic Value of Plasma Glucagon-like Peptide-1 Levels in Acute Myocardial Infarction

Important dates

Study start
2013
Primary completion
2015
Study completion
2015
First posted
Apr 26, 2017
Registry last updated
Oct 4, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.